SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Canaccord Genuity Downgrades Botanix Pharmaceuticals to Hold

Canaccord Genuity cut its rating on Botanix Pharmaceuticals from Buy to Hold.

BOT
SquawkNews Desk 1 updates Updated Oct 27, 2026, 11:55 PM UTC

Story updates

11:55:41 PM UTC
SquawkNews
Botanix Pharmaceuticals Price Target Cut 93% to A$0.01/Share by Canaccord Genuity

Related stories

Lennar Revolving Credit Facility Capacity Rises to $4.55 Billion A SEC filing says Lennar’s borrowing capacity under its revolving credit facility increased to $4.55 billion. M impact | EQUITY | Oct 29, 2026, 08:49 PM UTC GoDaddy Reports Q3 Profit of $261.8 Million GoDaddy said third-quarter profit rose from $210.5 million, or $1.51 per share, a year earlier, to $261.8 million, or $2.08 per share. M impact | EQUITY | Oct 29, 2026, 08:49 PM UTC Monolithic Power Systems forecasts Q4 2026 revenue of $1.315B-$1.385B M impact | EQUITY | Oct 29, 2026, 08:48 PM UTC Starbucks Expects About $1 Billion in Share Repurchases The CFO said Starbucks expects to deploy approximately $1 billion toward share repurchases. M impact | EQUITY | Oct 29, 2026, 08:48 PM UTC MasTec Q3 Revenue Beats Estimates on Power Delivery Strength MasTec’s third-quarter revenue beat estimates, supported by strength in its power delivery segment. M impact | EQUITY | Oct 29, 2026, 08:48 PM UTC Monolithic Power Systems Q3 revenue reaches $1,202.409 million Q3 revenue was $1,202.409 million, versus the IBES estimate of $1,145 million. M impact | EQUITY | Oct 29, 2026, 08:48 PM UTC